Antiplatelet and antithrombotic activity of indole-3-carbinol in vitro and in vivo

Phytotherapy Research

Volumn 22, Issue 1, 2008, Pages 58-64

  Park, Min Kyu ^a   Rhee, Yun Hee ^a   Lee, Hyo Jung ^a   Lee, Eun Ok ^a   Kim, Kwan Hyun ^a   Park, Min Jong ^a   Jeon, Byung Hun ^b   Shim, Bum Sang ^a   Jung, Chang Hyun ^a   Choi, Seung Hoon ^a   Ahn, Kyoo Seok ^a   Kim, Sung Hoon ^a  

^a Kyung Hee University   (South Korea)

^b Wonkwang University   (South Korea)

Author keywords

Antiplatelet activity; Antithrombotic agent; Glycoprotein IIb IIIa; Indole 3 carbinol; Thromboxane B2

Indexed keywords

3 INDOLEMETHANOL; ADRENALIN; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; COLLAGEN; FIBRINOGEN; FIBRINOGEN RECEPTOR; PROSTAGLANDIN E2; THROMBOXANE B2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; FLOW CYTOMETRY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INSTITUTE FOR CANCER RESEARCH MOUSE; LUNG EMBOLISM; MALE; MORTALITY; MOUSE; MOUSE STRAIN; NONHUMAN; STATISTICAL SIGNIFICANCE; THROMBOCYTE AGGREGATION; THROMBOCYTE RICH PLASMA; THROMBOEMBOLISM;

ANIMALS; COLLAGEN; DINOPROSTONE; DOSE-RESPONSE RELATIONSHIP, DRUG; EPINEPHRINE; FIBRINOGEN; FIBRINOLYTIC AGENTS; FLOW CYTOMETRY; HUMANS; INDOLES; MICE; MOLECULAR STRUCTURE; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PROTEIN BINDING; THROMBOXANE B2;

MUS;

EID: 38549099570     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.2260     Document Type: Article

References (26)

1. Born GV, Wehmeier A. 1979. Inhibition of platelet thrombus formation by chloropromazine acting to diminish haemolysis. Nature 282: 212-213.
2. Carughi A. 1997. Antiproliferative effect of a blend of extracts from cruciferous vegetables on human breast cancer. FASEB J 11: A397.
3. Cipollone F. 2005. COX-2 and prostaglandins in atherosclerosis. Lupus 14: 756-759.
4. Corti R, Farkouh ME, Baddimon JJ. 2002. The vulnerable plaque and acute coronary syndromes. Am J Med 113: 668-680.
5. Corti R, Fuster V, Baddimon JJ. 2003. Pathogenic concepts of acute coronary syndromes. J Am Coll Cadiol 41: 7S-14S.
6. Cowan DH. 1981. Platelet adherence to collagen: role of prostaglandin-thromboxane synthesis. Br J Haematol 49: 425-434.
7. Cryan LM, Pidgeon GP, Fitzgerald DJ et al. 2006. COX-2 protects against thrombosis of the retinal vasculature in a mouse model of proliferative retinopathy. Mol Vis 12: 405-414.
8. DiMinno G, Silver MJ. 1983. Mouse antithrombotic assay: a sample method for evaluation of antithrombotic agents in vivo. Potentiation of antithrombotic activity by ethyl alcohol. J Pharmacol Exp Ther 225: 57-60.
9. Fabre JE, Nguyen M, Athirakul K et al. 2001. Activation of the murine EP3 receptor for PGE2 inhibits cAMP production and promotes platelet aggregation. J Clin Invest 107: 603-610.
10. Macmahon S, Sharpe N. 1991. Long-term antiplatelet therapy for the prevention of vascular disease. Med J Aust 154: 477-480.
11. Murray JC, Kelly MA, Gorlick PB. 1994. Ticlopidine, a new antiplatelet agent for the secondary prevention of stroke. Clin Neuropharmacol 17: 23-31.
12. Mustard JF. 1975. Platelets, thrombosis and drugs. Drugs 9: 19-76.
13. Naimushin YA, Mazurov AV. 2005. Ability of different glycoprotein IIb-IIIa ligands to support platelet aggregation induced by activating antibody CRC54. Biochemistry (Mosc) 70: 782-789.
14. Nishizawa E, Wynalda DJ, Suydam DE et al. 1972. Collagen-induced pulmonary thromboembolism in mice. Thromb Res 1: 233-242.
15. Ozben B, Ekmekci A, Bugra Z et al. 2006. Multiple coronary thrombosis and stent implantation to the subtotally occluded right renal artery in a patient with essential thrombocytosis: a case report with review. J Thromb Thrombolysis 22: 79-84.
16. Packham MA. 1994. Role of platelets in thrombosis and hematosis. Can J Physiol Pharmacol 72: 278-284.
17. Packham MA, Mustard JF. 2005. Platelet aggregation and adenosine diphosphate/adenosine triphosphate receptors: a historical prospective. Semin Thromb Hemost 31: 129-138.
18. Peter K, Schwarz M, Ylanne J et al. 1998. Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa (alphaIIbbeta3) inhibitors. Blood 92: 3240-3249.
19. Petrusewicz J, Siluk D, Kaliszan R et al. 1999. Comparative study of antithrombotic and antiaggregatory activity of acetylsalicylic acid, ticlopidine and a new noncarboxylic acid antiinflammatory pyrazine derivative HF90. Acta Pol Pharm 56: 463-467.
20. Simmons DL, Botting RM, Hla T. 2004. Cyclooxygenase isozymes: The biology of prostaglandin synthesis and inhibition. Pharmacol Rev 56: 387-437.
21. Stein B, Fuster V. 1989. Role of platelet inhibitor therapy on myocardial infarction. Cardiovasc Drugs Ther 3: 797-813.
22. Stoewsand GS. 1995. Bioactive organosulfur phytochemicals in Brassica oleracea vegetables. Food Chem Toxicol 33: 537-543.
23. Straub A, Azevedo R, Beierlein W et al. 2005. Glycoprotein IIb/IIIa inhibition reduces prothrombotic events under conditions of deep hypothermic circulatory arrest. Thromb Haemost 94: 115-122.
24. Takada Y, Andreeff M, Aggarwal BB. 2005. Indole-3-carbinol suppresses NF-kappaB and IkappaBalpha kinase activation, causing inhibition of expression of NF-kappaB-regulated antiapoptotic and metastatic gene products and enhancement of apoptosis in myeloid and leukemia cells. Blood 106: 641-649.
25. Wang WY, Wu YC, Wu CC. 2006. Prevention of platelet glycoprotein IIb/IIIa activation by 3,4-methylenedioxy-beta-nitrostyrene, a novel tyrosine kinase inhibitor. Mol Pharmacol 70: 1380-1389.
26. Wijeyewickrema LC, Berndt MC, Andrews RK. 2005. Snake venom probes of platelet adhesion receptors and their ligands. Toxicon 45: 1051-1061.